No Data
Jefferies Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $19
Jefferies Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $19
Arcutis Biotherapeutics Analyst Ratings
What Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Gain Is Not Telling You
Express News | Arcutis Biotherapeutics Inc - Zoryve Cream 0.15% Shows Favorable Safety and Tolerability in Ad Patients
Arcutis to Highlight Data From Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}